Author/Authors :
Nabizadeh, Azita Department of Pharmacoeconomics and Pharmaceutical Administration - Tehran University of Medical Sciences, Tehran, Iran , Amani, Bahman Department of Health Science Education Development - Tehran University of Medical Sciences, Tehran, Iran , Kadivar, Maliheh Division of Neonatology - Department of Pediatrics - Children’s Medical Center - Tehran University of Medical Sciences, Tehran, Iran , Toroski, Mahdi Department of Pharmacoeconomics and Pharmaceutical Administration - Tehran University of Medical Sciences, Tehran, Iran , Abdollahi Asl, Akbar Department of Pharmacoeconomics and Pharmaceutical Administration - Tehran University of Medical Sciences, Tehran, Iran , Bayazidi, Yahya Department of Pharmacoeconomics and Pharmaceutical Administration - Tehran University of Medical Sciences, Tehran, Iran , Mojahedian, Mahdi Department of Pharmacoeconomics and Pharmaceutical Administration - Tehran University of Medical Sciences, Tehran, Iran , Davari, Majid Pharmaceutical Management and Economics Research Center - Tehran University of Medical Sciences, Tehran, Iran
Abstract :
Gaucher’s disease (GD) is one of the most common lysosomal diseases in humans.
It results from β‐glucosidase deficiency and leads to necrosis, especially in
macrophages with the accumulation of glucosylceramidase in cells. Most of the
deleterious effects of the disease are seen in the liver, spleen, and bone marrow.
The aim of this study was to compare the efficacy of Imiglucerase with Eliglustat
in treating patients with GD. PubMed/Medline, Cochrane Library, Scopus, Web
of Science, Embase, and Google Scholar were searched from inception to August,
2018. Predefined inclusion criteria for included studies were based on search
methodology and are as follows: All randomized, quasi-randomized controlled,
and cohort studies about patients with GD Type 1 that Imiglucerase was compared
with Eliglustat were included. Two authors independently choose the papers based
on the inclusion criteria. From 2979 recognized studies, three studies including
two randomized clinical trials and one cohort study were recognized to meet the
inclusion criteria. The primary outcomes were hemoglobin level, platelets count,
liver, and spleen size, and the secondary outcomes were the immunological side
effects of the medicines and bone complications. The results showed that there is
no meaningful difference between the two medicines in terms of increasing blood
hemoglobin, platelets count, and reducing the liver and spleen size. The findings
of this review showed that both medicines are effective in the treatment of GD
Type 1 and there is no statistically significant difference between their efficacies.
